PL‐Relief TM plus Alleviates Atopic Dermatitis and Regulates Inflammatory Responses via Inhibiting NF‐κB Signaling Pathway
Chemistry & Biodiversity · 2024
DOI: 10.1002/cbdv.202400349 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2024. Verfasst von Xiaohan Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, Department of Biochemistry and Molecular Biology, School of Basic Medical…. Hauptthemen laut MEDLINE: Dermatitis, Atopic, NF-kappa B, Signal Transduction. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Municipal Health Commission, Shanghai CORDAY Biotechnology Co., LTD..
Abstract (Originalsprache)
Background
Atopic dermatitis (AD) has various detrimental effects on individuals with limited drug cure rates which necessitate the development of new treatment methods. PL‐Relief TM plus (PLR) is composed of SupraOlive, Crocus Sativus extracts and Citrus reticulata extracts. The effect of PLR on AD remains to be explored.
Methods
2,4‐dinitrofluorobenzene‐induced AD model mice were involved and the histopathology of the skin lesions was observed along with the levels of inflammatory chemokines levels were measured. To further validate the molecular mechanism of PLR, RNA‐seq was performed in HaCaT cells. Western blotting and immunofluorescence were performed to investigate NF‐κB signaling pathways response in AD.
Results
Due to PLR treatment, the thickening of the epidermis and dermis was inhibited and the number of eosinophils, mast cells, and CD4 + T cells in the skin lesion was decreased. In addition, the levels of inflammatory cytokines were decreased in dorsal skin tissues and LPS‐stimulated HaCat cells. Furthermore, KEGG pathway analysis suggested that most identified downstream biological functions were associated with inflammatory response. PLR inhibited NF‐κB signaling in AD mice and HaCaT cells.
Conclusions
These results indicate that PLR is a potent therapeutic agent for attenuating symptoms of AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, 200032, Shanghai, China.
- Shanghai CORDAY Biotechnology Co., LTD, 201403, Shanghai, China.
- Department of Breast Surgery, Fudan University Shanghai Cancer Center, 200032, Shanghai, China.
- Department of Oncology, Shanghai Medical College, Fudan University, 200032, Shanghai, China.
Förderung
- National Natural Science Foundation of China
- Shanghai Municipal Health Commission
- Shanghai CORDAY Biotechnology Co., LTD.
Zitieren
APA
Zhang, X., Shen, Z., Zhu, W., Lin, L., Fan, Y., Cheng, X., Yu, M., Yu, S., & Zhao, B. (2024). PL‐Relief TM plus Alleviates Atopic Dermatitis and Regulates Inflammatory Responses via Inhibiting NF‐κB Signaling Pathway. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202400349
Vancouver
Zhang X, Shen Z, Zhu W, Lin L, Fan Y, Cheng X, et al. PL‐Relief TM plus Alleviates Atopic Dermatitis and Regulates Inflammatory Responses via Inhibiting NF‐κB Signaling Pathway. Chemistry & Biodiversity. 2024. doi:10.1002/cbdv.202400349
BibTeX
@article{Zhang2024,
author = {Zhang, Xiaohan and Shen, Zhiyuan and Zhu, Wei and Lin, Lin and Fan, Yangyi and Cheng, Xiaoyu and Yu, Min and Yu, Sanjian and Zhao, Bing},
title = {PL‐Relief TM plus Alleviates Atopic Dermatitis and Regulates Inflammatory Responses via Inhibiting NF‐κB Signaling Pathway},
journal = {Chemistry & Biodiversity},
year = {2024},
doi = {10.1002/cbdv.202400349}
}
EUVIMED